Parkinsonism & related disorders · 2025
Fecal tyrosine decarboxylase and motor response complications in Parkinson's disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hor Jia Wei, Lim Shen-Yang, Toh Tzi Shin, Chong Chun Wie, Teh Cindy Shuan Ju, Song Sze Looi, Tan Ai Huey
Аннотация
INTRODUCTION: Gut microbe-derived tyrosine decarboxylase (TDC) was recently discovered to metabolize levodopa, potentially reducing its bioavailability and aggravating motor dysfunction in Parkinson's disease (PD) through fluctuating dopaminergic stimulation. We aimed to investigate the clinical significance of fecal tdc (TDC gene) abundance in PD patients, focusing on its association with motor response complications (MRC).
METHODS: Fecal samples were collected from 178 PD patients (mean age = 67.7 ± 8.7years; median Hoehn and Yahr stage = 2.0[1.0]; median disease duration = 7.0[8.0]years) who underwent evaluations of motor severity (MDS-UPDRS), cognitive function (MoCA), and constipation severity (PAC-SYM). Fecal tdc abundance was quantified via real-time polymerase chain reaction.
RESULTS: Fecal tdc abundance showed high interindividual variability, with a trend for higher levels in patients with MRC (n = 85) compared to those without (n = 93) (median [IQR], 1.6 × 108 [21.3 × 108] vs. 0.6 × 108 [7.0 × 108], p = 0.109; mean difference 10.1 × 108 [95 % CI: -8.7 × 108, 28.9 × 108], p = 0.293). Patients with dyskinesia and motor fluctuations had 2.9-fold and 2.3-fold higher fecal tdc abundances, respectively, compared to those without, although differences were not significant. In the overall cohort, fecal tdc abundance correlated mildly with levodopa equivalent daily dose (LEDD, rs = 0.16, p = 0.035). A similar mild correlation with LEDD was observed in the subgroup of patients with motor fluctuations (rs = 0.22, p = 0.045).
CONCLUSIONS: Elevated fecal tdc abundance may be associated with higher levodopa requirements in PD. However, no statistically significant association was found with MRC. Further investigations are warranted to explore its utility as a disease biomarker and/or therapeutic target in PD.
METHODS: Fecal samples were collected from 178 PD patients (mean age = 67.7 ± 8.7years; median Hoehn and Yahr stage = 2.0[1.0]; median disease duration = 7.0[8.0]years) who underwent evaluations of motor severity (MDS-UPDRS), cognitive function (MoCA), and constipation severity (PAC-SYM). Fecal tdc abundance was quantified via real-time polymerase chain reaction.
RESULTS: Fecal tdc abundance showed high interindividual variability, with a trend for higher levels in patients with MRC (n = 85) compared to those without (n = 93) (median [IQR], 1.6 × 108 [21.3 × 108] vs. 0.6 × 108 [7.0 × 108], p = 0.109; mean difference 10.1 × 108 [95 % CI: -8.7 × 108, 28.9 × 108], p = 0.293). Patients with dyskinesia and motor fluctuations had 2.9-fold and 2.3-fold higher fecal tdc abundances, respectively, compared to those without, although differences were not significant. In the overall cohort, fecal tdc abundance correlated mildly with levodopa equivalent daily dose (LEDD, rs = 0.16, p = 0.035). A similar mild correlation with LEDD was observed in the subgroup of patients with motor fluctuations (rs = 0.22, p = 0.045).
CONCLUSIONS: Elevated fecal tdc abundance may be associated with higher levodopa requirements in PD. However, no statistically significant association was found with MRC. Further investigations are warranted to explore its utility as a disease biomarker and/or therapeutic target in PD.